tradingkey.logo

Vivus Announces Enrollment Of First Patient In Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine As A Component Of High-Dose Chemotherapy Prior To Transplant In Patients With Hodgkin Or Non-Hodgkin Lymphoma

ReutersApr 14, 2025 2:16 PM

-

  • VIVUS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL ASSESSING ETHANOL-FREE CARMUSTINE AS A COMPONENT OF HIGH-DOSE CHEMOTHERAPY PRIOR TO TRANSPLANT IN PATIENTS WITH HODGKIN OR NON-HODGKIN LYMPHOMA

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles